RxDoctor Payments Data

Richard Rayford, MD

Cardiovascular Disease · Flowood, MSNPI 1760496467

Payments from drug & device makers

$2,570in general payments, 2019–2025

Across 143 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$679
  • Novartis$446
  • Amgen$254
  • Boehringer Ingelheim$189
  • Pfizer$160
  • Amarin Pharma, Inc.$154
  • plus $688 from 17 others

What the payments were for

  • Food & beverage$2,52298%
  • Education$110%
  • Entertainment$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,570 in reported general payments places this provider in the 35th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$59,488
Medicare patients
223
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$136,039
EntrestoSacubitril/Valsartan103$106,126
XareltoRivaroxaban43$38,451
FarxigaDapagliflozin Propanediol25$22,221
BrilintaTicagrelor30$18,506
MultaqDronedarone Hcl14$10,568
Colesevelam Hcl27$3,324
Metoprolol Succinate244$2,939
Atacand HctCandesartan/Hydrochlorothiazid22$1,567
Rosuvastatin Calcium76$1,461
Atorvastatin Calcium171$1,168
Nitroglycerin74$1,156
Digoxin32$980
Potassium Chloride59$890
Carvedilol143$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$136,039147 claims
NovartisEntresto$446$106,126103 claims
AstraZenecaFarxiga, Brilinta$141$40,72755 claims
Johnson & JohnsonXarelto$72$38,45143 claims
Sanofi-aventis U.S. LLCMultaq$15$10,56814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →